EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience

Jules P J Douwes iD, Erik F Hensen iD, Jeroen C Jansen iD, Hans Gelderblom iD, Josefine E Schopman iD

Cancers · 12.04.2024 · 16 (8) · 1479

DOI: 10.3390/cancers16081479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 12.04.2024. Verfasst von Jules P J Douwes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

NF2-related schwannomatosis, characterized by the development of bilateral vestibular schwannomas, often necessitates varied treatment approaches. Bevacizumab, though widely utilized, demonstrates variable effectiveness on hearing and tumor growth. At the same time, (serious) adverse events have been frequently reported. (2)

Methods

A single center retrospective study was conducted, on NF2-related schwannomatosis patients treated with bevacizumab from 2013 to 2023, with the aim to assess treatment-related and clinical outcomes. Outcomes of interest comprised hearing, radiologic response, symptoms, and adverse events. (3)

Results

Seventeen patients received 7.5 mg/kg bevacizumab for 7.1 months. Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss. Vestibular schwannoma regression occurred in 31%, and 69% remained stable. Further symptomatic improvement was reported by 41%, stable symptoms by 47%, and worsened symptoms by 12%. Treatment discontinuation due to adverse events was observed in 29% of cases. Hypertension (82%) and fatigue (29%) were most frequently reported, with no occurrences of grade 4/5 toxicities. (4)

Conclusion

Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.

Schlagwörter

Stichwörter der Autor:innen

acoustic neuromaadverse eventsbevacizumabcerebellopontine angle tumorhearingneurofibromatosis type 2schwannomatosistumor responsevestibular schwannoma

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Department of Medical Oncology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

ORCID-Profile: Jules P J Douwes, Erik F Hensen, Jeroen C Jansen, Hans Gelderblom, Josefine E Schopman

Zitieren

APA

Douwes, J. P. J., Hensen, E. F., Jansen, J. C., Gelderblom, H., & Schopman, J. E. (2024). Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience. Cancers, 16(8), 1479. https://doi.org/10.3390/cancers16081479

Vancouver

Douwes JPJ, Hensen EF, Jansen JC, Gelderblom H, Schopman JE. Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience. Cancers. 2024;16(8):1479. doi:10.3390/cancers16081479

BibTeX
@article{Douwes2024,
  author = {Douwes, Jules P J and Hensen, Erik F and Jansen, Jeroen C and Gelderblom, Hans and Schopman, Josefine E},
  title = {Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {8},
  pages = {1479},
  doi = {10.3390/cancers16081479}
}
Kostenlos starten →